Saturday, October 31, 2026

American Public Education Stock Soars 32% In 21 Sessions

ViaNews Editorial Team

January 24, 2024

American Public Education Stock Soars 32% In 21 Sessions

(VIANEWS) -

About American Public Education

American Public Education, Inc. is an education provider offering both online and campus-based postsecondary education and career learning for postsecondary education and career advancement. Operating three segments -- American Public University System, Rasmussen University and Hondros College of Nursing -- it offers degree and certificate programs across a wide array of areas such as nursing, public health, public administration and business administration as well as nursing- and health sciences-oriented diploma in practical nursing training and an associate degree program for their nursing and health sciences-focused students. Established in 1991 in Charles Town West Virginia this company began operations three segments -- American Public University System | Rasmussen University | Hondros College Of Nursing | Hondros College Of Nursing | Hondros College Of Nursing | Hondros College Of Nursing | Hondros College Of Nursing | Hondros College Of Nursing | Charles Town | West Virginia |

Yearly Analysis

Based on the available data, here is an investment outlook for American Public Education stock: Yearly Top and Bottom Value At present, the stock is trading at EUR11.95, which is below its 52-week high of EUR13.51 but above its 52-week low of EUR3.76, indicating it has performed better year over year. Anticipated Sales Growth This year, sales are expected to experience negative 1.3% sales growth compared to last year; however, next year sales may experience 2.6% sales growth which indicates an uptick in revenues. Earnings Before Interest, Taxes, Depreciation and Amortization EBITDA stands at EUR16.7, providing an indicator of profitability. But to make an informed investment decision it is also essential to take into account other financial metrics and factors like debt levels, cash flows and general health of the business. Based on this initial evaluation, American Public Education appears to be an attractive medium-risk investment opportunity. However, for an informed investment decision it would be prudent to conduct further analysis of their finances and other factors related to them.

Technical Analysis

American Public Education Inc. (APEI) is currently trading above both its 50-day and 200-day moving averages, signalling a bullish trend in its price. Last reported volume was 21.52% lower than its typical daily volume of 104,363, suggesting reduced trading activity compared to its typical day. American Public Education's intraday variation averaged 2.51% over the last week, 1.94% over the past month and 4.81% over the last quarter, with its highest amplitude reaching 4.18% for one week, 3.40% for a month and 4.81% over an entire quarter. According to the stochastic oscillator, American Public Education stock is considered oversold (=20), offering potential buying opportunities. Investors should proceed cautiously and conduct in-depth research prior to making any investments decisions.

Quarter Analysis

Sales GrowthAmerican Public Education's sales growth for this quarter was negative 1.3% and estimated growth for next quarter is anticipated at 0.6%. Quarter GrowthEstimates are set at 137.1% while growth for future quarters are estimated to reach 92.1%. Revenue GrowthAmerican Public Education reported year-on-year quarterly revenue growth of 0.9% year over year over twelve months, currently accounting for 600.18M in revenue.

Equity Analysis

As an AI language model, I can offer you an investment outlook for American Public Education based on the information you provided. Please keep in mind that this does not constitute financial advice and if making investment decisions should always consult a licensed financial advisor prior to making any definitive decisions. American Public Education currently has an EPS of EUR-3.9 and negative return on equity of -22.4% over its last 12 month track record, indicating it may not be an ideal investment opportunity at present. Earnings per Share (EPS) is a key financial metric that measures how much profit a company generates for each outstanding share of stock it holds. American Public Education's negative EPS indicates that shareholders are not receiving adequate returns on their investments at American Public Education. Additionally, their negative return on equity suggests their investments may not provide adequate returns to satisfy shareholders. Overall, investors may wish to carefully consider these factors before making decisions regarding American Public Education as an investment option. It may be prudent for them to wait until American Public Education can demonstrate consistent profitability and positive returns on equity before considering an investment option in them.

More news about American Public Education (APEI).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com